Stassets Investment Leads Round with Major Contribution, Joined by LSK Investment and Shinhan Capital

Investment Provides Crucial Resources for Company's Focus on Developing Small Molecule Synthetic New Drugs in Synthetic Lethality, DNA Damage Response, and Cell Cycle Sectors

First-In-Class AD1208 Preclinical Results Announced at AACR in April

SEOUL,...